The clinical quality indicators for haemophilia are:
The clinical quality indicator for the proportion of patients under care of our haemophilia centre with severe haemophilia A or B, who have an annual assessment of their musculoskeletal system.
People with haemophilia are at risk of bleeding into joints or muscle, which reduces their quality of life and leads to additional treatment with costly recombinant clotting factors.
Regular assessment of the musculoskeletal system provides an opportunity to identify and address problems that have potential to lead to joint or muscle bleeds.
We aim to assess over 90% of patients with haemophilia.
The clinical quality indicator for the proportion of patients assessed and treated within 45 minutes of their appointment time in the warfarin monitoring clinic.
We have recently introduced 'point-of-care' testing to improve the efficiency of our warfarin monitoring service.
Regular monitoring of anti-coagulation for patients taking warfarin is important for safe and efficacious treatment. Patients visit the anti-coagulation clinic between eight and 12 times per year, and in some instances as often as once every week to monitor the effect of the warfarin and receive advice on changes to their dose.
Patient satisfaction is closely related to clinic waiting times and efficent communication of results and required dose changes.
National Patient Safety Agency: Alert 18, 2007
We aim to test and review warfarin doses within 45 minutes of the clinic appointment time in over 95% of patients attending the warfarin monitoring clinic.